Its frequent co-occurrence with adverse cytogenetic lesions, such as CK, MK, and aneuploidy, including del(5q), −5, and −7, contributes to its poor prognosis [23,26], alongside a low incidence of co-mutation with non-adverse mutations like FLT3, NPM1, and RAS gene mutations when compared to TP53 wild-type (TP53-WT) AML [29]. The gene discussed is TP53; the disease is acute myeloid leukemia.